Researchers from the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) investigated the ability of high doses of a specific molecule (CpG oligonucleotide) to successfully modulate the immune system’s allergic response, thereby inducing a tolerance-promoting reaction in patients that are known to be allergic to cats.
The researchers analyzed the molecular mechanisms underlying this tolerance and proposed a pre-clinical allergen-specific immunotherapy approach to improve the treatment and control of this common type of allergy. The full study results were published in the journal Allergy, the official journal of the European Academy of Allergy and Clinical Immunology (EAACI).
Leonard, C., et al. Comprehensive mapping of immune tolerance yields a regulatory TNF receptor 2 signature in a murine model of successful Fel d 1‐specific immunotherapy using high‐dose CpG adjuvant. Allergy, 2021; DOI: 10.1111/all.14716
